Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GRPH
- Price
- -
- Stock movement down
- -300.00 (-85.71%)
- Company name
- Graphite Bio Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.91B
- Ent value
- 2.73B
- Price/Sales
- 284.47
- Price/Book
- 15.86
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 205.25%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
GRPH does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 284.47 |
| Price to Book | 15.86 |
| EV to Sales | 266.79 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 58.24M |
| EPS (TTM) | -2.11 |
| FCF per share (TTM) | -1.74 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 10.24M |
| Gross profit (TTM) | 4.98M |
| Operating income (TTM) | -124.24M |
| Net income (TTM) | -122.14M |
| EPS (TTM) | -2.11 |
| EPS (1y forward) | -0.40 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 48.61% |
| Operating margin (TTM) | -1213.74% |
| Profit margin (TTM) | -1193.19% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 185.86M |
| Net receivables | 0.00 |
| Total current assets | 188.02M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 321.00K |
| Total assets | 188.46M |
| Accounts payable | 250.00K |
| Short/Current long term debt | 362.00K |
| Total current liabilities | 4.80M |
| Total liabilities | 4.87M |
| Shareholder's equity | 183.58M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -90.01M |
| Capital expenditures (TTM) | 10.86M |
| Free cash flow (TTM) | -100.86M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -66.53% |
| Return on Assets | -64.81% |
| Return on Invested Capital | -66.43% |
| Cash Return on Invested Capital | -54.86% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| GRPH | S&P500 | |
| Current price drop from All-time high | -85.71% | -0.19% |
| Highest price drop | -93.98% | -56.47% |
| Date of highest drop | 6 Jan 2023 | 9 Mar 2009 |
| Avg drop from high | -78.42% | -11.07% |
| Avg time to new high | 99 days | 12 days |
| Max time to new high | 682 days | 1805 days |
COMPANY DETAILS
Marketcap
2.91B
Marketcap category
Mid-cap
Description
As of March 21, 2024, Graphite Bio, Inc. was acquired by LENZ Therapeutics, Inc., in a reverse merger transaction. Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.
Employees
6
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner